CYP3A4 inhibitors like ranitidine and diltiazem and CYP3A4 inducers like efavirenz can increase and decrease exposure to<unk> , respectively. Concomitant use of<unk>  with strong CYP3A4 inhibitors or moderate or strong CYP3A4 inducers should be avoided, while it is recommended that the maximum dose of<unk>  be limited with moderate CYP3A4 inhibitors. Gastric pH modifiers like famotidine can decrease peak levels of<unk>  without affecting total exposure. Alcohol and selective serotonin reuptake inhibitors (SSRIs) like citalopram have not shown significant pharmacokinetic interactions with<unk> . Coadministration of<unk>  with other sedatives like benzodiazepines, opioids, tricyclic antidepressants, and alcohol may increase the risk of central nervous system depression and daytime impairment.<unk>  has not been found to significantly influence the pharmacokinetics of other drugs including midazolam (CYP3A4 substrate), rosuvastatin (BCRP substrate), and the SSRI citalopram.
Daridorexant
Seltorexant
Suvorexant
Veristrat
Bocasan
Toremifene
Icatibant
Fenproporex